Short answer
Niagen Bioscience, Inc. (NAGE) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Niagen Bioscience (NAGE) divesting its analytical reference standards and services business unit.
Niagen Bioscience, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Niagen Bioscience (NAGE) divesting its analytical reference standards and services business unit
- Asset sale signals strategic pivot: likely narrowing focus to core bioscience/NAD+ related operations
- Full deal terms, price, and buyer identity expected in press release Exhibit 99.1
Item 8.01 · Other Events
- All-cash divestiture of analytical reference standards and services business to VHG Labs (LGC Group), closed Feb 24, 2026
- Deal aligns with stated strategy to exit non-core assets and concentrate on NAD+ science platform, IP, and commercial growth
- No purchase price disclosed in this filing: key valuation data absent for investor assessment
- 6-month transition services agreement included, with Sellers receiving a service fee from Buyer post-close
- Strategic narrowing reduces revenue diversification but signals sharper focus on core TRU NIAGEN/NAD+ commercial business
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Niagen Bioscience, Inc. 8-K filings
Get the next NAGE 8-K as it lands
Follow NAGE for push alerts, or ask the research agent what this filing means.